Medpace Holdings, Inc.MEDPEarnings & Financial Report
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Revenue
$511.0M
Gross Profit
N/A
Operating Profit
$104.1M
Net Profit
$102.6M
Gross Margin
N/A
Operating Margin
20.4%
Net Margin
20.1%
YoY Growth
17.7%
EPS
$3.20
Medpace Holdings, Inc. Q1 FY2024 Financial Summary
Medpace Holdings, Inc. reported revenue of $511.0M (up 17.7% YoY) for Q1 FY2024, with a net profit of $102.6M (up 40.7% YoY) (20.1% margin).
Key Financial Metrics
| Total Revenue | $511.0M |
|---|---|
| Net Profit | $102.6M |
| Gross Margin | N/A |
| Operating Margin | 20.4% |
| Report Period | Q1 FY2024 |
Medpace Holdings, Inc. Annual Revenue by Year
Medpace Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.5B).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.5B |
| 2024 | $2.1B |
| 2023 | $1.9B |
| 2022 | $1.5B |
Medpace Holdings, Inc. Quarterly Revenue & Net Profit History
Medpace Holdings, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $708.5M | +32.0% | $135.1M | 19.1% |
| Q3 FY2025 | $659.9M | +23.7% | $111.1M | 16.8% |
| Q2 FY2025 | $603.3M | +14.2% | $90.3M | 15.0% |
| Q1 FY2025 | $558.6M | +9.3% | $114.6M | 20.5% |
| Q4 FY2024 | $536.6M | +7.7% | $117.0M | 21.8% |
| Q3 FY2024 | $533.3M | +8.3% | $96.4M | 18.1% |
| Q2 FY2024 | $528.1M | +14.6% | $88.4M | 16.7% |
| Q1 FY2024 | $511.0M | +17.7% | $102.6M | 20.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $511.0M | $528.1M | $533.3M | $536.6M | $558.6M | $603.3M | $659.9M | $708.5M |
| YoY Growth | 17.7% | 14.6% | 8.3% | 7.7% | 9.3% | 14.2% | 23.7% | 32.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.80B | $1.92B | $2.08B | $2.10B | $1.90B | $1.57B | $1.75B | $1.98B |
| Liabilities | $1.12B | $1.16B | $1.20B | $1.28B | $1.30B | $1.40B | $1.46B | $1.52B |
| Equity | $671.5M | $763.6M | $881.4M | $825.5M | $593.6M | $172.4M | $293.6M | $459.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $152.7M | $116.4M | $149.1M | $190.7M | $125.8M | $148.5M | $246.2M | $192.7M |